费城 (Ph) 阴性骨髓增生性肿瘤 (MPN)，即原发性血小板增多症 (ET)、真性红细胞增多症 (PV) 和原发性骨髓纤维化 (PMF)，是一组慢性克隆性造血疾病，有发展为骨髓衰竭的倾向或急性髓性白血病；常常导致死亡。尽管已经在这些 MPN 中发现了驱动突变，但该疾病的亚型特异性标志物尚未发现。新一代测序 (NGS) 技术可以同时筛查许多疾病相关基因，从而有可能改善 MPN 的临床管理。

The Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs), namely essential thrombocythaemia (ET), polycythaemia vera (PV) and primary myelofibrosis (PMF), are a group of chronic clonal haematopoietic disorders that have the propensity to advance into bone marrow failure or acute myeloid leukaemia; often resulting in fatality. Although driver mutations have been identified in these MPNs, subtype-specific markers of the disease have yet to be discovered. Next-generation sequencing (NGS) technology can potentially improve the clinical management of MPNs by allowing for the simultaneous screening of many disease-associated genes.